Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + vinorelbine + bevacizumab
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a multi-agent oncology regimen combining docetaxel, vinorelbine, and bevacizumab. Docetaxel is a taxane that stabilizes microtubules and prevents depolymerization, causing mitotic arrest. Vinorelbine is a vinca alkaloid that inhibits microtubule polymerization by binding tubulin, disrupting mitotic spindle formation. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A) to inhibit angiogenesis. The combination has been explored primarily in non-small cell lung cancer (NSCLC), including as adjuvant therapy after resection and in advanced non-squamous NSCLC in combinations containing bevacizumab; docetaxel–vinorelbine doublets have also been studied in metastatic breast cancer. This triplet is not a branded fixed-dose combination; it is an investigational regimen assembled from three approved agents for cancer therapy.
- Other names
- docetaxel plus vinorelbine plus bevacizumabDOC + VIN + BEV
02
Targets
VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + vinorelbine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + vinorelbine + bevacizumab.